Open AccessSoluble Urokinase Plasminogen Activator Receptor for Risk Prediction in Patients Admitted with Acute Chest Pain
Author(s) -
Stig Lyngbæk,
Charlotte Andersson,
Jacob Louis Marott,
Daniél V. Møller,
Michael Christiansen,
Kasper Iversen,
Peter Clemmensen,
Jesper EugenOlsen,
Peter Riis Hansen,
Jørgen Jeppesen
Publication year - 2013
Publication title -
clinical chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.705
H-Index - 218
eISSN - 1530-8561
pISSN - 0009-9147
DOI - 10.1373/clinchem.2013.203778
Subject(s) - supar , medicine , myocardial infarction , chest pain , cardiology , hazard ratio , st elevation , acute coronary syndrome , unstable angina , diabetes mellitus , urokinase , urokinase receptor , endocrinology , confidence interval
Plasma concentrations of soluble urokinase plasminogen activator receptor (suPAR) predict mortality in several clinical settings, but the long-term prognostic importance of suPAR in chest pain patients admitted on suspicion of non-ST-segment elevation acute coronary syndrome (NSTEACS) is uncertain.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom